Denali Therapeutics Inc. Shareholders' Equity
Denali Therapeutics Inc. (DNLI) had Shareholders' Equity of $835.18 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $835.18M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $926.10M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $1.01B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $926.20M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $835.18M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $926.10M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $1.01B 10-Q · filed 2026-08-06 |
| 2025-09-30 | $926.20M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.03B 10-Q · filed 2026-08-06 |
| 2025-03-31 | $1.12B 10-Q · filed 2026-08-06 |
| 2024-12-31 | $1.23B 10-Q · filed 2026-08-06 |
| 2024-09-30 | $1.32B 10-Q · filed 2025-11-06 |
| 2024-06-30 | $1.39B 10-Q · filed 2025-11-06 |
| 2024-03-31 | $1.46B 10-Q · filed 2025-08-11 |
| 2023-12-31 | $1.03B 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.12B 10-Q · filed 2024-11-06 |
| 2023-06-30 | $1.19B 10-Q · filed 2024-11-06 |
| 2023-03-31 | $966.71M 10-Q · filed 2024-08-01 |
| 2022-12-31 | $1.04B 10-K · filed 2026-02-26 |
| 2022-09-30 | $811.30M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $884.45M 10-Q · filed 2023-11-07 |
| 2022-03-31 | $917.93M 10-Q · filed 2023-08-08 |
| 2021-12-31 | $962.29M 10-K · filed 2025-02-27 |
| 2021-09-30 | $1.01B 10-Q · filed 2022-11-03 |
| 2021-06-30 | $1.07B 10-Q · filed 2022-11-03 |
| 2021-03-31 | $1.11B 10-Q · filed 2022-08-08 |
| 2020-12-31 | $1.15B 10-K · filed 2024-02-28 |
| 2020-09-30 | $882.55M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $502.17M 10-Q · filed 2021-11-04 |
| 2020-03-31 | $545.31M 10-Q · filed 2021-08-04 |
| 2019-12-31 | $394.89M 10-K · filed 2023-02-27 |
| 2019-09-30 | $438.20M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $475.17M 10-Q · filed 2020-11-05 |
| 2019-03-31 | $516.65M 10-Q · filed 2020-08-07 |
| 2018-12-31 | $546.85M 10-K · filed 2022-02-28 |
| 2018-09-30 | $461.18M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $490.27M 10-Q · filed 2019-11-06 |
| 2018-03-31 | $539.03M 10-Q · filed 2019-08-06 |
| 2017-12-31 | $465.80M 10-K · filed 2021-02-26 |
| 2016-12-31 | -$94.15M 10-K · filed 2020-02-27 |
| 2015-12-31 | -$15.63M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |